Previous 10 | Next 10 |
Gainers: Greenwich LifeSciences ( GLSI ) +41% . Histogen ( HSTO ) +37% . Oramed Pharmaceuticals ( ORMP ) +25% . InMode ( INMD ) +13% . Annexon ( ANNX ) +11% . Losers: Can-Fite BioPharma ( CANF ) -11% . Arc...
Histogen ( HSTO ) +78% . Canoo ( GOEV ) +74% after signing a deal with Walmart for 4,500 all electric delivery vehicles. Novo Integrated Sciences ( NVOS ) +14% expects to report over fivefold increase in Q3 revenue. Annexon ( ANNX ) +13% p...
Annexon ( NASDAQ: ANNX ) stock gained 10% premarket on Tuesday after the biopharmaceutical firm extended its cash runway into H2 of 2025 following the closing of a $130M private placement . Proceeds from the private placement, along with ANNX's current c...
BRISBANE, Calif., July 11, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced...
Sometimes the best penny stocks to buy are the ones that nobody is looking at (yet). The last few months of stock market trends have certainly shown that anything can happen, and even good news can make a surprising impact on stocks. Today, the latest round of economic data came out thanks ...
Annexon ( NASDAQ: ANNX ) entered into a securities purchase agreement for a private placement that is expected to result in gross proceeds of ~$130M. The company is selling 9.01M shares, pre-funded warrants to purchase up to 24.7M shares and accompanying warrants to purcha...
BRISBANE, Calif., July 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced...
The following slide deck was published by Annexon, Inc. in conjunction with this event. For further details see: Annexon (ANNX) Corporate Presentation - Slideshow
Annexon (NASDAQ:ANNX) said final data from a phase 2 trial of ANX005 in patients with Huntington’s disease (HD) showed that disease progression stabilized in the nine-month study. HD is a rare, genetic disease which causes progressive degeneration of nerve cells in the brain, leading t...
ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated Disease Progression Stabilized in Overall Patient Population Through the Nine-month Study Rapid Improvement in Clinical Outcome Measures Maintained in Patients with High Baseline Complement A...
News, Short Squeeze, Breakout and More Instantly...
Protective Effects of ANX007 on Visual Acuity and Vision Related Anatomical Measures in the Central Macula Will be Presented as a Late-Breaking Oral Presentation Topline Phase 2 ARCHER Trial Results Will be Discussed as an Oral Presentation BRISBANE, Calif., July 11, 2024 (GLOBE N...
ANX005-Treated Patients Demonstrated Faster and More Complete Recovery from Week 1 through Week 26 on Primary and Multiple Pre-Specified Endpoints Two and a Half Times More ANX005-Treated Patients Returned to a Normal / Pre-Disease State of Health Over Placebo on GBS-DS by Week 26, Increa...
Single Infusion of ANX005 Demonstrated Significant Improvements Across Multiple Functional and Prognostic Measures That Expedited Recovery in GBS Patients ANX005 Has Potential to be the First Targeted Therapy Approved for the Treatment of GBS BRISBANE, Calif., June 18, 2024 (GLOBE...